Cancer Genetics and StemoniX Announce Merger Closing
31 mars 2021 06h30 HE
|
Cancer Genetics, Inc.
Cancer Genetics, Inc. Renamed to Vyant Bio, Inc. Vyant Bio, Inc. will begin trading on Nasdaq under the symbol VYNT CHERRY HILL, N.J., March 31, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc....
Cancer Genetics Announces Shareholder Approval of All Proposals in Connection with the Proposed Merger with StemoniX
25 mars 2021 09h15 HE
|
Cancer Genetics, Inc.
Combined entity creates an innovative platform to de-risk and accelerate the discovery and development of preclinical and clinical pipelines with biopharma partners as well as the proprietary pipeline...
Cancer Genetics to Present at the Annual 33rd ROTH Conference
12 mars 2021 09h30 HE
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts,...
Cancer Genetics to Present at the H.C. Wainwright Global Life Sciences Conference
04 mars 2021 16h15 HE
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts,...
Cancer Genetics Announces Closing of $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules
16 févr. 2021 16h45 HE
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today...
Cancer Genetics Announces $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules
10 févr. 2021 23h00 HE
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today...
Cancer Genetics Announces Closing of $10.0 Million Private Placement Priced At-the-Market
01 févr. 2021 17h16 HE
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today...
Cancer Genetics Announces $10.0 Million Private Placement Priced At-the-Market
28 janv. 2021 16h02 HE
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today...
Cancer Genetics to Present at the 2021 BioConnect Virtual Conference Hosted by H.C. Wainwright
07 janv. 2021 16h05 HE
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts,...
Cancer Genetics Reports Third Quarter 2020 Financial Results
12 nov. 2020 16h25 HE
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, announced...